Non-Hodgkin Lymphoma B008

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838

Last amended

Factors in CCPS as at 12 May 2010 (B008)

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/rulebase-non-hodgkins-lymphoma

Last amended

Being on land in Vietnam or in Vietnamese waters or consuming Vietnamese water

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/being-land-vietnam-or-vietnamese-waters-or-consuming-vietnamese-water

Coeliac disease

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/coeliac-disease

HTLV-1 infection

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/htlv-1-infection

Inability to obtain appropriate clinical management for non-Hodgkin's lymphoma

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/inability-obtain-appropriate-clinical-management-non-hodgkins-lymphoma

Infection with Helicobacter pylori

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/infection-helicobacter-pylori

Infection with the human immunodeficiency virus (HIV)

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/infection-human-immunodeficiency-virus-hiv

Solid organ or bone marrow transplant

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/solid-organ-or-bone-marrow-transplant

Spraying or decanting a herbicide

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/spraying-or-decanting-herbicide

Systemic immunosuppressive drug therapy

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/systemic-immunosuppressive-drug-therapy

Treatment for Hodgkin's lymphoma

Current RMA Instruments
Reasonable Hypothesis SOP
90 of 2018 as amended
Balance of Probabilities SOP
91 of 2018 as amended
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 202.8
  • ICD-10-AM Codes: C82 to C85
Brief description

Non-Hodgkin Lymphoma (NHL) covers a group of malignancies of the T or B lymphocytes within lymphoid tissue or lymph nodes.  

Confirming the diagnosis

The diagnosis is complex and generally requires excision biopsy of a lymph node with histologic, immunologic, and molecular biologic assessment.

The relevant medical specialist is a haematologist or oncologist.

Additional diagnoses covered by these SOPs
  • Adult T cell lymphoma/leukaemia
  • Other named lymphomas that are not Hodgkin’s lymphoma, small lymphocytic lymphoma or lymphoblastic lymphoma and are not excluded by the SOP definition
  • Burkitt’s lymphoma
  • MALT (mucosal associated lymphoid tissue) Lymphoma
  • Mycosis fungoides – T cell lymphoma of the skin
  • Richter’s syndrome. This is where chronic lymphocytic leukaemia transforms to non-Hodgkin’s lymphoma. There is a specific factor for this in the SOP
  • Splenic marginal zone lymphoma (B cell)
  • Sezary’s disease/Sezary’s syndrome – This is a cutaneous T cell lymphoma
Conditions not covered by these SOPs  
  • Acute lymphoblastic leukaemia/lymphoblastic lymphoma*
  • Chronic lymphocytic leukaemia/small lymphocytic lymphoma*
  • Hairy cell leukaemia* - Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • Hodgkin's lymphoma*
  • Myeloma*
  • Plasma cell malignancy* - Myeloma
  • Waldenstrom’s macroglobulinaemia#                    

* another SOP applies

# non-SOP condition

Clinical onset

The clinical presentation is extremely variable.  Initial symptoms tend to be non-specific (e.g. weight loss, fever, night sweats).  Detection of a mass or enlarged lymph nodes is the most common presentation. Once the diagnosis has been confirmed, onset can be backdated to the first detection of the relevant mass/lump or the first symptoms that can be attributed to the condition.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  The natural course of the condition depends on the specific type of NHL and a range of other prognostic factors.  Inability to obtain appropriate management could lead to a worsening of the condition in the form of faster disease progression.  Relapse after an initial treatment-induced remission is common.

 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/n-p/non-hodgkins-lymphoma-b008-c82c830-c836c838/rulebase-non-hodgkins-lymphoma/treatment-hodgkins-lymphoma